Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications

1

Datopotamab deruxtecan (Dato-DXd) is a TROP2-targeting antibody-drug conjugate (ADC) combining a monoclonal antibody and a topoisomerase I inhibitor.
2

Dato-DXd has shown compelling efficacy and a manageable safety profile in clinical trials for various solid tumors.
3

The FDA approved Dato-DXd for treating HR+/HER2- breast cancer and EGFR-mutant non-small cell lung cancer.
4

TROP2 is overexpressed in many solid tumors, making it a valuable therapeutic target due to its association with poor prognosis.
5

Ongoing research aims to optimize Dato-DXd's clinical application, including sequencing strategies and overcoming drug resistance.

1